BPC-157 + TB-500 5+5mg

What is BPC-157 + TB-500 ?

This is a pre-blended vial of BPC-157 5mg and TB-500 5mg: 10mg of BPC-157/TB-500 powder in one lyophilised vial, under batch UKPL-2237. It is also written BPC157 TB500 or BPC 157 TB 500. One vial means one reconstitution and one solution for designs that use both peptides.

TB-500 and BPC-157 are chemically unrelated. BPC-157 is a 15-residue peptide taken from a protein first found in human gastric juice. TB-500 is specified here as N-acetylated thymosin beta 4, 43 residues. Each has its own product page covering its mechanism and literature.

What matters for the blend is format. Co-formulation saves preparation steps but removes independent control of each peptide. Equal mass is also not equal moles. No controlled study has tested this combination.

BPC-157 + TB-500 Research Applications

• BPC-157 signalling : VEGFR2 upregulation and internalisation in human endothelial cells (Hsieh et al., J Mol Med, 2017).
• Thymosin beta 4 signalling : a complex with PINCH and integrin-linked kinase that activates Akt, with cardiomyocyte migration and survival in mouse heart models (Bock-Marquette et al., Nature, 2004).
• Human evidence : a 2025 scoping review found only three small pilot studies of BPC-157 in humans and no large-scale trials (McGuire et al., Curr Rev Musculoskelet Med).

The blend suits preclinical soft-tissue and cell-migration designs that would otherwise run both peptides in parallel preparations. Its value is one reconstitution and one in-use window. No property arises from co-formulation itself, and no study has compared the pair against either peptide alone.

Pre-Blended Vial vs Two Separate Vials

The blend wins on procedure. One vial needs one reconstitution and one fill volume, so there is no transfer step to add sterility risk or volume error. Both peptides share one reconstitution date. Separate vials win when the ratio must vary, when an effect has to be pinned to one peptide, or when only one is needed. Separate vials also make the molar imbalance obvious. 5mg of BPC-157 at 1419.53 g/mol is about 3.5 µmol, while 5mg of TB-500 at 4963.4 g/mol is about 1.0 µmol. The certificate for a blend also has to measure each peptide separately.

Research Overview

This is the pre-blended presentation, a single lyophilised vial containing BPC-157 5mg and TB-500 5mg, batch UKPL-2237. It is written various ways across the literature and the market, BPC 157 TB 500, BPC157 TB500, or simply the BPC-157 and TB-500 blend, and all refer to this same co-formulated vial. The pairing is also widely searched under its community nickname, the Wolverine stack, a forum name rather than a scientific term, and that too refers to this vial. The two compounds are chemically unrelated and their individual mechanisms and literatures are documented on the separate BPC-157 and TB-500 pages. What this page covers is the blend as a format, meaning what co-formulation gives a researcher and what it removes. What it gives is procedural. One vial means one reconstitution, one fill volume and one solution, which eliminates a transfer step along with its sterility and volumetric error from a combined-preparation design, and it means both components share a single reconstitution date and a single in-use window. What it removes is independent control, and there is an arithmetic consequence worth stating plainly. An equal-mass blend is not an equimolar blend. BPC-157 is a 15-residue pentadecapeptide at 1419.53 g/mol, while TB-500 is the 43-residue thymosin beta 4 sequence at 4963.4 g/mol. Five milligrams of each therefore corresponds to approximately 3.5 µmol of BPC-157 against approximately 1.0 µmol of TB-500, a molar ratio near 3.5 to 1 rather than 1 to 1, and any calculation expressed in molar terms has to account for that. The honest position on the pairing is that no controlled study has evaluated this specific combination. Both compounds have substantial independent preclinical literatures and are frequently run alongside one another in tissue-repair designs because the reported mechanisms are distinct rather than redundant, but combination-specific data does not exist. Separate vials remain preferable wherever the two need to be varied independently or an observation attributed to one mechanism. Research use only.

Storage and Reconstitution

Keep sealed vials at -20°C, away from light and moisture. After reconstitution, keep the solution at 2-8°C and use it within 4 weeks, or freeze single-use aliquots at -20°C. Both peptides share one reconstitution date, so the shorter in-use window governs the whole vial. Freeze-thaw cycles cut recovery of the thymosin beta 4 chain in particular.

Vials are sold on their own, without bacteriostatic water for mixing or other supplies.

How to reconstitute and handle

Treat the vial as one 10mg preparation, with the fill volume set by the concentration your protocol needs. Let the vial and the bacteriostatic water reach room temperature and swab both stoppers. Add the water slowly down the inside wall and swirl gently until dissolved. Do not shake or vortex: the thymosin beta 4 chain is shear-sensitive. The solution should be clear and colourless. The two peptides cannot be separated after reconstitution. Label the vial with fill volume, concentration and date.

• Treat the vial as 10mg of total peptide at a fixed internal ratio. The blend cannot be split into its components after reconstitution, so a protocol requiring the two at an independently chosen ratio needs separate vials rather than this format.
• Work in molar terms with care. Equal masses of a 1419.53 g/mol peptide and a 4963.4 g/mol peptide give a molar ratio near 3.5 to 1, not 1 to 1, so mass-based and mole-based descriptions of this vial are not interchangeable.
• Introduce the diluent slowly down the inner glass wall and swirl gently until the solution is clear and colourless. The 43-residue thymosin beta 4 chain in particular is shear sensitive, and agitation reduces recovery of intact peptide.
• Both components share one reconstitution date, so the shorter of the two in-use windows governs the vial.
• Aliquot into single-use volumes and avoid repeated freeze-thaw cycles. Verify on the certificate of analysis that both components have been resolved and assayed separately rather than reported as a single combined figure.

For the full method, see the peptide reconstitution guide and the reconstitution calculator.

Research References

• Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017)
• Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004)
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (McGuire et al., Curr Rev Musculoskelet Med, 2025)

Published research on BPC-157 + TB-500 is indexed on PubMed. See our full UK buyer's guide for BPC-157 + TB-500 and UK buyer's guide for Wolverine Stack.